Metabolic Consequences of Moderate Weight Gain - Role of Dietary Fat Composition (LIPOGAIN)

NCT ID: NCT01427140

Last Updated: 2011-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the metabolic consequences of a moderate weight gain and if the type of dietary fat (saturated versus polyunsaturated) can modify the effects in young healthy adults. Hypothesis: the type of dietary fat can modify the effects of weight gain.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Specific goals:

* Investigate if dietary fat composition influences liver fat accumulation and metabolic risk factors in response to moderate weight gain
* Investigate if polyunsaturated fat (PUFA) in the diet could counteract any unfavorable metabolic changes that are expected to accompany moderate weight gain
* Investigate effects of weight gain and dietary fat composition on markers of vascular health

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Liver fat Polyunsaturated fatty acids (PUFA) Saturated fatty acids (SFA) Weight gain Overfeed Dietary fatty acids Palm oil Sunflower oil

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Saturated fatty acid group

Addition of saturated fatty acids to the diet inte the form of pastries

Group Type ACTIVE_COMPARATOR

Saturated fatty acid group

Intervention Type OTHER

Addition of saturated fatty acids to the diet in the form of pastries

Polyunsaturated fatty acid group

Addition of polyunsaturated fatty acids to the diet in the form of pastries

Group Type ACTIVE_COMPARATOR

Polyunsaturated fatty acid group

Intervention Type OTHER

Addition of polyunsaturated fatty acids to the diet in the form of pastries

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Polyunsaturated fatty acid group

Addition of polyunsaturated fatty acids to the diet in the form of pastries

Intervention Type OTHER

Saturated fatty acid group

Addition of saturated fatty acids to the diet in the form of pastries

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy,
* Body Mass Index 18-27

Exclusion Criteria

* Liver disease,
* Coronary heart disease,
* Diabetes mellitus,
* Malignant diseases,
* Alcohol or drug abuse,
* Magnetic Resonance-incompatibility,
* Abnormal clinical chemistry,
* Use of drugs that significantly effects energy metabolism,
* Heavy exercise,
* Pregnancy or lactation,
* Allergy of gluten, egg or milk protein
Minimum Eligible Age

20 Years

Maximum Eligible Age

38 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Uppsala University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ulf Risérus, Ass. professor

Role: PRINCIPAL_INVESTIGATOR

Clinical Nutrition and Metabolism, Dept. of Public Health and Caring Sciences, Uppsala University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Uppsala University Hospital, Uppsala Science Park

Uppsala, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

References

Explore related publications, articles, or registry entries linked to this study.

Rosqvist F, Orho-Melander M, Kullberg J, Iggman D, Johansson HE, Cedernaes J, Ahlstrom H, Riserus U. Abdominal Fat and Metabolic Health Markers but Not PNPLA3 Genotype Predicts Liver Fat Accumulation in Response to Excess Intake of Energy and Saturated Fat in Healthy Individuals. Front Nutr. 2020 Dec 3;7:606004. doi: 10.3389/fnut.2020.606004. eCollection 2020.

Reference Type DERIVED
PMID: 33344496 (View on PubMed)

Perfilyev A, Dahlman I, Gillberg L, Rosqvist F, Iggman D, Volkov P, Nilsson E, Riserus U, Ling C. Impact of polyunsaturated and saturated fat overfeeding on the DNA-methylation pattern in human adipose tissue: a randomized controlled trial. Am J Clin Nutr. 2017 Apr;105(4):991-1000. doi: 10.3945/ajcn.116.143164. Epub 2017 Mar 8.

Reference Type DERIVED
PMID: 28275132 (View on PubMed)

Iggman D, Rosqvist F, Larsson A, Arnlov J, Beckman L, Rudling M, Riserus U. Role of dietary fats in modulating cardiometabolic risk during moderate weight gain: a randomized double-blind overfeeding trial (LIPOGAIN study). J Am Heart Assoc. 2014 Oct 15;3(5):e001095. doi: 10.1161/JAHA.114.001095.

Reference Type DERIVED
PMID: 25319187 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SLS-2011-LPG

Identifier Type: -

Identifier Source: org_study_id